Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Camp4 Therapeutics (CAMP) EBIT Margin (2023 - 2025)

Camp4 Therapeutics (CAMP) has disclosed EBIT Margin for 3 consecutive years, with 3671.26% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 151881.0% to 3671.26% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1502.43% through Dec 2025, up 663975.0% year-over-year, with the annual reading at 1502.43% for FY2025, 663990.0% up from the prior year.
  • EBIT Margin hit 3671.26% in Q4 2025 for Camp4 Therapeutics, down from 1717.11% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 870.27% in Q2 2025 to a low of 3671.26% in Q4 2025.
  • Historically, EBIT Margin has averaged 2243.84% across 3 years, with a median of 1934.78% in 2024.
  • Biggest YoY gain for EBIT Margin was -151881bps in 2025; the steepest drop was -151881bps in 2025.
  • Year by year, EBIT Margin stood at 3525.14% in 2023, then soared by 39bps to 2152.45% in 2024, then crashed by -71bps to 3671.26% in 2025.
  • Business Quant data shows EBIT Margin for CAMP at 3671.26% in Q4 2025, 1717.11% in Q3 2025, and 870.27% in Q2 2025.